Lumiradx has commenced shipments in europe for its covid-19 & flu a/b microfluidic antigen test

London, jan. 11, 2022 /prnewswire/ -- lumiradx (nasdaq: lmdx), a next-generation point of care diagnostics company, today announced preliminary results for the fourth quarter of 2021 as well as expected full-year revenue. the company anticipates 2021 full-year revenues of $422 million compared to 2020 revenues of $139 million and 2021 fourth quarter revenues of $119 million compared to 2020 fourth quarter revenues of $101 million.
LMDX Ratings Summary
LMDX Quant Ranking